Corbus Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery

Press Release Webcast
About

About

Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates.

Learn More
Technology

Technology

Our technology is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.

Learn More
Indications

Indications

Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with chronic inflammatory and fibrotic conditions.

Learn More

Pipeline

Our pipeline is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.

View Details

Lenabasum

Multi-system Inflammatory

Systemic Sclerosis

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Launch Phase not started

Targeting 2021 launch

Multi-system Inflammatory

Dermatomyositis

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Launch Phase not started

Multi-system Inflammatory

Systemic Lupus Erythematosus

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Launch Phase not started
Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Launch Phase not started

CRB-4001

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Launch Phase not started

Scheduled to Enter Phase 1 in 2019, NIH Committed to Funding Phase 2 Study.

Preclinical library (more than 600 compounds)

Goal: 1-2 new Phase 1 programs per year starting in 2020

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Launch Phase not started

Lenabasum

A novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes.

Sign up for
Email Alerts

Receive breaking news first!

Sign up today

Investor
Presentation

Fact
Sheet